Basic Stats
| LEI | 549300LMDE3RUP8Z3L60 |
| CIK | 1567892 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mallinckrodt PLC
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 August 19, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 20, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 As filed with the Securities and Exchange Commission on August 14, 2025 Registration No. |
|
| August 14, 2025 |
Exhibit 10.4 [Director Form] Mallinckrodt Pharmaceuticals 2025 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on , 202 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [] Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Comp |
|
| August 14, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Mallinckrodt plc Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, $0. |
|
| August 14, 2025 |
Exhibit 10.3 [Employee and Executive Form] Mallinckrodt Pharmaceuticals 2025 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on , 202 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [] Restricted Units subject to the provisions of these Terms and Conditions and the |
|
| August 14, 2025 |
Exhibit 10.2 [CEO Inducement Grant] Mallinckrodt Pharmaceuticals 2025 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on August , 2025 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [] Restricted Units subject to the provisions of these Terms and Conditions and the |
|
| August 14, 2025 |
Exhibit 4.3 MALLINCKRODT PHARMACEUTICALS 2025 STOCK AND INCENTIVE PLAN Effective August 13, 2025 Article I PURPOSE 1.1 Purpose. The purposes of this Plan are to promote the interests of the Company by (i) aiding in the recruitment and retention of Directors, Employees and Consultants, (ii) providing incentives to Directors, Employees and Consultants by means of performance-related incen |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 August 13, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 July 31, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 27, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35803 Mallinckrodt plc (Exa |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
Form of Deed of Indemnification Agreement by and between Mallinckrodt plc and Officers. Exhibit 10.2 MNK PLC FORM FOR MALLINCKRODT PLC OFFICERS DEED OF INDEMNIFICATION THIS DEED OF INDEMNIFICATION (this “Agreement”), dated as of , 20, is made by and between Mallinckrodt plc, a public limited company incorporated in Ireland, and (“Indemnitee”). WHEREAS, it is essential to Mallinckrodt plc to retain and attract as personnel the most capable persons available; WHEREAS, Indemnitee is an |
|
| August 6, 2025 |
Exhibit 10.2 [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Second Amended and Restated RESTRICTED UNIT AWARD AMENDMENT #1 RESTRICTED UNIT AWARD (“Award”) granted on February 19, 2024 (the “Grant Date”) as amended and restated as of August 5, 2024, and as further amended and restated as of December 2, 2024, is hereby further amended as o |
|
| August 6, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Tyndall as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign (i) one or more Registration Statements including on Form S-8 (and any and all amendments thereto, in |
|
| August 6, 2025 |
endo993 Exhibit 99.3 Management’s Discussion and Analysis of Financial Condition and Results of Operations The following Management’s Discussion and Analysis of Financial Condition and Results of Operations describes the principal factors affecting our financial condition at June 30, 2025 and results of operations for the Successor three and six months ended June 30, 2025 and 2024, the Predecessor |
|
| August 6, 2025 |
Exhibit 10.1 [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Second Amended and Restated RESTRICTED UNIT AWARD AMENDMENT #1 RESTRICTED UNIT AWARD (“Award”) granted on February 2, 2024 (the “Grant Date”), as amended and restated as of August 5, 2024, and as further amended and restated as of December 2, 2024, is hereby further ame |
|
| August 6, 2025 |
Exhibit 99.1 Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance Legacy Mallinckrodt Second Quarter 2025 Results Delivers Second Quarter Net Sales of $485.1 Million, Reflecting a 5.7% Year-Over-Year Decrease on a Reported Basis; Excluding Impact of Therakos® Divestiture, Net Sales Grew 8.5% Reports Net Income of $2.4 Million and Adjusted EBITDA of $137.2 Millio |
|
| August 6, 2025 |
endo992 Exhibit 99.2 ENDO, INC. INDEX Condensed Consolidated Balance Sheets as of June 30, 2025 (Successor) and December 31, 2024 (Successor) (Unaudited) 2 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 (Successor), the three and six months ended June 30, 2024 (Successor), the period April 1, 2024 to April 23, 2024 (Predecessor) and the period Janu |
|
| August 6, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on August 1, 2025 (the “Effective Date”) by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto (the “Company”), and Christiana Stamoulis (the “Executive”) (collectively referred to as “Parties” or individually referred to as a “Party”). WHEREAS, the Company |
|
| August 1, 2025 |
Par Health Deal - basis financial information presentation Exhibit 99.3 Par Health Deal - basis financial information presentation Table of contents 2 July 2025 | Par Health Page 2 Summary of findings Business overview Quality of earnings Recast income statement Working capital Appendix 1 2 3 4 5 6 3 10 16 48 69 78 Summary of findings Standalone and synergies Diligence adjusted gross profit Diligence adjusted net sales Diligence EBITDA $(35.0)m $728.5m $1 |
|
| August 1, 2025 |
Exhibit 10.1 EXECUTION VERSION $1,350,000,000 CREDIT AGREEMENT Dated as of July 31, 2025 among MEH, INC., as the Borrower, ST 2020, INC., as the Parent, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral Agent, THE LENDERS PARTY HERETO, GOLDMAN SACHS BANK USA, as Arranger and Bookrunner, and OPY CREDIT COR |
|
| August 1, 2025 |
Form of Deed of Indemnification by and between Mallinckrodt plc and Directors and Secretary. Exhibit 10.1 PLC FORM FOR MALLINCKRODT PLC DIRECTORS/SECRETARY DEED OF INDEMNIFICATION THIS DEED OF INDEMNIFICATION (this “Agreement”), dated as of , 20, is made by and between Mallinckrodt plc, a public limited company incorporated in Ireland, and (“Indemnitee”). WHEREAS, it is essential to Mallinckrodt plc to retain and attract as directors and secretary the most capable persons availabl |
|
| August 1, 2025 |
Exhibit 10.2 SUCAMPO FORM FOR MALLINCKRODT PLC DIRECTORS/SECRETARY INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of , 20, is made by and between Sucampo Pharmaceuticals LLC, a Delaware limited liability company (“Sucampo”), and (“Indemnitee”). WHEREAS, Sucampo is a wholly owned subsidiary of Mallinckrodt plc, a public limited company incorporated in |
|
| August 1, 2025 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 99.5 EXECUTION VERSION AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (including all exhibits hereto and as may be amended, supplemented or restated from time to time in accordance with the terms hereof, this “Agreement”) is made and entered into as of the Effective Date, by and among Mallinckrodt plc, an Irish public limited comp |
|
| August 1, 2025 |
Certain Preliminary Financial Information Exhibit 99.4 Certain Preliminary Financial Information The following preliminary financial information for the 2nd quarter of fiscal year 2025 was provided to certain shareholders on July 10, 2025. · Consolidated Revenue is favorable to the model with all segments above or at forecast · Consolidated PF Adj. EBITDA is ~$5-6mm off model forecast with favorability from MNK Gx being offset by Endo Si |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 July 31, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 1, 2025 |
Amended and Restated Memorandum and Articles of Association of Mallinckrodt plc. Exhibit 3.1 Companies Act 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM and ARTICLES OF ASSOCIATION of MALLINCKRODT PUBLIC LIMITED COMPANY (as amended by Special Resolution passed on 13 June 2025 with effect from 31 July 2025) DUBLIN Cert. No.: 522227 Companies Act 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION of MALLINCKRODT PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION 1. The name |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 July 31, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) ( |
|
| August 1, 2025 |
Exhibit 99.2 Confidential and subject to change Par Health Confidential and subject to change Par Health Transaction Overview Confidential and subject to change Par Health Confidential and subject to change Transaction Summary Confidential and subject to change Par Health 1. PF. Adj. EBITDA burdened by $35mm of forecasted annual net dissynergies Transaction Summary 1 Sources New $200mm Revolver $ |
|
| August 1, 2025 |
Exhibit 99.1 Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo’s Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of 2025 New York Stock Exchange (NYSE) Listing |
|
| July 31, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 7, 2025 |
Exhibit 10.1 THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT This THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), is entered into on July 7, 2025 and shall be effective on the Effective Date, as defined below, by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto (the “Company”), and Sigurdur Olafsson (the “Executive”). WHEREAS, t |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 13, 2025 |
Exhibit 99.1 Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader Mallinckrodt to Apply to Irish High Court for Approval of Scheme of Arrangement DUBLIN and MALVERN, Pa., June 13, 2025 /PRNewswire/ – Mallinckrodt plc (“Mallinckrodt”) and Endo, Inc. (OTCQX: NDOI) (“Endo”) today announced that their respective shareholders have provide |
|
| June 13, 2025 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 13, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 9, 2025 |
Exhibit 99.1 Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses Generics & Sterile Injectables Spin-Off to be Called Par Health DUBLIN and MALVERN, Pa., June 9, 2025 – Mallinckrodt plc (“Mallinckrodt”) and Endo, Inc. (OTCQX: NDOI) (“En |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 9, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 9, 2025 Date of Report (Date of Earliest Event Reported) Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 9, 2025 |
Exhibit 99.1 Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses Generics & Sterile Injectables Spin-Off to be Called Par Health DUBLIN and MALVERN, Pa., June 9, 2025 – Mallinckrodt plc (“Mallinckrodt”) and Endo, Inc. (OTCQX: NDOI) (“En |
|
| May 30, 2025 |
Exhibit 1.01 Conflict Minerals Report Introduction Mallinckrodt plc is a global business consisting of multiple wholly owned subsidiaries (collectively, “Mallinckrodt” or “the Company”) that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. The Company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in speci |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 (State or other jurisdiction of incorporation) (Commission File Number) College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland (Address of principal executive offices) (Zip |
|
| May 16, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Form S-4 No. 333-286694 Subject Company: Endo, Inc. (Commission File No. 333-280767) P22993 - EPB ALL VOTES MATTER PLEASE VOTE FOR BOTH THE COURT MEETING AND THE EGM TODAY! GO VOTE BUSINESS COMBINATION WITH EN |
|
| May 16, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Form S-4 No. 333-286694 Subject Company: Endo, Inc. (Commission File No. 333-280767) Mallinckrodt and Endo Announce Significant Progress in Proposed Merger S-4 Registration Statement Effective; HSR Waiting Per |
|
| May 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Form S-4 No. 333-286694 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Colleagues, I’m pleased to report today exciting news regarding our planned merger with Endo to create a global, scaled |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35803 Mallinckrodt plc (Ex |
|
| May 12, 2025 |
Endo, Inc. 9 Great Valley Parkway Malvern, Pennsylvania 19355 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration File No. 333-286694 Endo, Inc. 9 Great Valley Parkway Malvern, Pennsylvania 19355 May 12, 2025 Dear Endo Stockholder: You are cordially invited to attend a special meeting of the stockholders (the “Endo special meeting”) of Endo, Inc. (“Endo”), to be held on June 13, 2025 at 9.00 a.m., Eastern Time, at 9 Great Valley Parkway, Malver |
|
| May 9, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Form S-4 No. 333-286694 Subject Company: Endo, Inc. (Commission File No. 333-280767) Mallinckrodt (Q1 2025) May 6, 2025 Corporate Speakers: · Siggi Olafsson; Mallinckrodt PLC; Chief Executive Officer · Bryan R |
|
| May 8, 2025 |
Form of Proxy Card of Mallinckrodt, plc Court Meetings.** Exhibit 99.1 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. C/O MALLINCKRODT PLC COMPANY SECRETARY COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH, BLANCHARDSTOWN DUBLIN 15, IRELAND VOTE BY INTER |
|
| May 8, 2025 |
Exhibit 99.7 200 West Street | New York, NY 10282-2198 Tel: 212-902-1000 | Fax: 212-902-3000 May 8, 2025 Board of Directors Endo, Inc. 1400 Atwater Drive Malvern, PA 19355 Re: Amendment No. 2 (the “Amendment”) to Registration Statement on Form S-4 of Mallinckrodt plc (File No. 333-286694) (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated March 13, |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
Consent of Lazard Frères & Co. LLC** Exhibit 99.6 The Board of Directors Mallinckrodt plc College Business & Technology Park, Cruiserath Blanchardstown, Dublin 15, Ireland The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated March 13, 2025, to the Board of Directors of Mallinckrodt plc (“Mallinckrodt”) as Annex F to, and reference thereto under the headings “SUMMARY — Opinion of Mallinckrodt’s Finan |
|
| May 8, 2025 |
[Letterhead of Mallinckrodt plc] May 8, 2025 [Letterhead of Mallinckrodt plc] May 8, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| May 8, 2025 |
Form of Proxy Card of Endo, Inc.** Exhibit 99.3 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V75347-Z90334 ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ENDO, INC. 9 GREAT VALLEY PARKWAY MALVERN, PA. 19355 ! ! ! ! ! ! ! ! ! ! ! ! 1. The |
|
| May 6, 2025 |
Form of Proxy Card of Mallinckrodt, plc Court Meeting.** Exhibit 99.1 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. C/O MALLINCKRODT PLC COMPANY SECRETARY COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH, BLANCHARDSTOWN DUBLIN 15, IRELAND VOTE BY INTER |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 6, 2025 |
Form of Proxy Card of Mallinckrodt, plc Extraordinary General Meeting.* Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature [PLEASE SIGN WITHIN BOX] Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: The Board of Directors recommends you vote FOR each of the following proposals at the Extraordinary General Meeting: Extraordinary General Meeting Proxy Card Please date and sign name exactly as it appears hereon. Executors, administrators, truste |
|
| May 6, 2025 |
Exhibit 99.1 Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance Delivers First Quarter Net Sales of $419.9 Million, Reflecting a 10%Year-Over-Year Decrease on a Reported Basis; Excluding Impact of Therakos® Divestiture, Net Sales Grew 2.5% Reports Net Loss of $27.7 Million and Adjusted EBITDA of $102.3 Million Acthar® Gel (repository corticotropin inject |
|
| May 6, 2025 |
Consent of Lazard Frères & Co. LLC** Exhibit 99.6 The Board of Directors Mallinckrodt plc College Business & Technology Park, Cruiserath Blanchardstown, Dublin 15, Ireland The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated March 13, 2025, to the Board of Directors of Mallinckrodt plc (“Mallinckrodt”) as Annex F to, and reference thereto under the headings “SUMMARY — Opinion of Mallinckrodt’s Finan |
|
| May 6, 2025 |
Exhibit 99.7 200 West Street | New York, NY 10282-2198 Tel: 212-902-1000 | Fax: 212-902-3000 May 6, 2025 Board of Directors Endo, Inc. 1400 Atwater Drive Malvern, PA 19355 Re: Amendment No. 1 (the “Amendment”) to Registration Statement on Form S-4 of Mallinckrodt plc (File No. 333-286694) (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated March 13, |
|
| May 6, 2025 |
Exhibit 21.2 SUBSIDIARIES OF ENDO, INC. The following is a list of the subsidiaries of Endo, Inc. as of December 31, 2024. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo, Inc. Endo Finance Holdings, Inc. Delaware Direct Endo Enterprise, Inc. Delaware Indirect Paladin Pharma Inc. Canada Indirect Endo USA, Inc. Delaware Indirect Endo US Holdings Luxembourg I S.a.r.l. Luxe |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 6, 2025 |
Exhibit 99.1 Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance Delivers First Quarter Net Sales of $419.9 Million, Reflecting a 10%Year-Over-Year Decrease on a Reported Basis; Excluding Impact of Therakos® Divestiture, Net Sales Grew 2.5% Reports Net Loss of $27.7 Million and Adjusted EBITDA of $102.3 Million Acthar® Gel (repository corticotropin inject |
|
| May 6, 2025 |
Exhibit 99.10 Consent of Prospective Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statement on Form S-4 of Mallinckrodt plc (the “Registrant”), and all amendment or supplements thereto (the “Registration Statement”), as a person who is to become a director of the Registrant effective as of |
|
| May 6, 2025 |
Exhibit 99.9 Consent of Prospective Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statement on Form S-4 of Mallinckrodt plc (the “Registrant”), and all amendment or supplements thereto (the “Registration Statement”), as a person who is to become a director of the Registrant effective as of |
|
| May 6, 2025 |
Exhibit 99.11 Consent of Prospective Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statement on Form S-4 of Mallinckrodt plc (the “Registrant”), and all amendment or supplements thereto (the “Registration Statement”), as a person who is to become a director of the Registrant effective as of |
|
| May 6, 2025 |
As filed with the Securities and Exchange Commission on May 6, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 6, 2025 Registration No. |
|
| May 6, 2025 |
Form of Proxy Card of Endo, Inc.** Exhibit 99.3 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V75347-Z90334 ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ENDO, INC. 9 GREAT VALLEY PARKWAY MALVERN, PA. 19355 ! ! ! ! ! ! ! ! ! ! ! ! 1. The |
|
| May 6, 2025 |
[Letterhead of Wachtell, Lipton, Rosen & Katz] [Letterhead of Wachtell, Lipton, Rosen & Katz] May 6, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| April 23, 2025 |
Exhibit 99.8 Consent of Prospective Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statement on Form S-4 of Mallinckrodt plc (the “Registrant”), and all amendment or supplements thereto (the “Registration Statement”), as a person who is to become a director of the Registrant effective as of |
|
| April 23, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Form S-4 No. 333-286694 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Colleagues, When we announced the exciting news last month of our planned merger with Endo, we committed to keeping the |
|
| April 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Mallinckrodt plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| April 23, 2025 |
Exhibit 99.7 200 West Street | New York, NY 10282-2198 Tel: 212-902-1000 | Fax: 212-902-3000 April 23, 2025 Board of Directors Endo, Inc. 1400 Atwater Drive Malvern, PA 19355 Re: Registration Statement on Form S-4 of Mallinckrodt plc, filed April 23, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated March 13, 2025 (“Opinion Letter”), with resp |
|
| April 23, 2025 |
As filed with the Securities and Exchange Commission on April 23, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 23, 2025 Registration No. |
|
| April 23, 2025 |
Consent of Lazard Frères & Co. LLC Exhibit 99.6 The Board of Directors Mallinckrodt plc College Business & Technology Park, Cruiserath Blanchardstown, Dublin 15, Ireland The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated March 13, 2025, to the Board of Directors of Mallinckrodt plc (“Mallinckrodt”) as Annex F to, and reference thereto under the headings “SUMMARY — Opinion of Mallinckrodt’s Finan |
|
| April 3, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 24, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Mallinckrodt(March 18 Town Hall) March 19, 2025* Corporate Speakers: · Joyce Pearl; Director Commercial Communications · Sigurdur Olafsson; Mallinckro |
|
| March 18, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Mallinckrodt (Town Hall) March 13, 2025* Corporate Speakers: · Sigurdur Olafsson; Mallinckrodt Pharmaceuticals; Chief Executive Officer, President PRE |
|
| March 18, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Valued Mallinckrodt Partner, I am reaching out to share some exciting news regarding Mallinckrodt. We recently announced that we have agreed to c |
|
| March 14, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Mallinckrodt and Endo Q4 2024 Earnings and Joint Transaction Call Transcript March 13, 2025 Companies’ Participants: Laure E. Park - Senior Vice Presi |
|
| March 13, 2025 |
Exhibit 99.1 Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance Achieved High End of Full-Year Net Sales Guidance Range and Midpoint of Adjusted EBITDA Guidance Range Grew Full-Year Net Sales by 6.1% to $2.0 Billion, with 14.2% Growth in Acthar® Gel (repository corticotropin injection) and 15.4% Growth in Specialty Generics; Reduced Total Debt |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Valued Mallinckrodt Partner, I am pleased to share some exciting news regarding Mallinckrodt. We just announced that we have agreed to combine wi |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) |
|
| March 13, 2025 |
Exhibit 99.3 CONFIDENTIAL Project Salvare DISCUSSION MATERIALS FEBRUARY 2025 CONFIDENTIAL Table of Contents PROJECT SALVARE Preliminary Value Creation Analysis of a Potential Transaction Overview of a Potential Generics Separation 4 Appendix Strategic Perspectives on a Potential Transaction 2 3 1 Executive Summary PROJECT SALVARE 3 Preliminary and Illustrative • Given the clear alignment of the Ma |
|
| March 13, 2025 |
Exhibit 99.2 Creating a Global, Scaled, Diversified Pharmaceuticals Leader 1 March 13, 2025 Disclosures No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such of |
|
| March 13, 2025 |
FORM OF VOTING AND SUPPORT AGREEMENT Exhibit 99.1 FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 13, 2025 (the “Agreement Date”), by and among (i) Mallinckrodt plc, a public limited company incorporated in Ireland (hereinafter called “Macaw”), (ii) Endo, Inc., a Delaware corporation (hereinafter called “Eagle”), and (iii) [ ], a shareholder of Eagle ( |
|
| March 13, 2025 |
FORM OF VOTING AND SUPPORT AGREEMENT Exhibit 99.1 FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 13, 2025 (the “Agreement Date”), by and among (i) Mallinckrodt plc, a public limited company incorporated in Ireland (hereinafter called “Macaw”), (ii) Endo, Inc., a Delaware corporation (hereinafter called “Eagle”), and (iii) [ ], a shareholder of Eagle ( |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 13, 2025 |
Exhibit 2.1 EXECUTION VERSION TRANSACTION AGREEMENT by and among Mallinckrodt plc, Endo, Inc., and Salvare Merger Sub LLC, dated as of March 13, 2025 TABLE OF CONTENTS 1. INTERPRETATION 2 1.1 Certain Definitions 2 1.2 Terms Defined Elsewhere 22 1.3 Construction 24 1.4 Captions 25 1.5 Time 25 2. SCHEME 25 2.1 Scheme 25 2.2 Change in Shares 25 3. IMPLEMENTATION OF THE SCHEME; COURT MEETINGs AND EGM |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Colleagues, We just announced that we are embarking on the next exciting stage in our evolution by combining with Endo, Inc. This transaction is |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Mallinckrodt R&D Partner, I’m reaching out to share some exciting news regarding Mallinckrodt. We just announced that we have agreed to combine w |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Employee FAQ 1. What did Mallinckrodt announce? · We announced that Mallinckrodt has agreed to combine with Endo, Inc. · Endo is a diversified pharmac |
|
| March 13, 2025 |
Exhibit 99.2 Creating a Global, Scaled, Diversified Pharmaceuticals Leader 0 March 13, 2025 Disclosures No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such of |
|
| March 13, 2025 |
Exhibit 99.1 Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader Transaction Brings Together Two Highly Complementary Businesses to Broaden Patient Access and Develop New Therapies to Address Unmet Patient Needs Combined Company Expected to Benefit from Immediate Scale, Robust Cash Flow and Enhanced Financial Flexibility to Invest in Internal and Externa |
|
| March 13, 2025 |
Exhibit 10.18 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTATED RESTR |
|
| March 13, 2025 |
Exhibit 99.3 CONFIDENTIAL Project Salvare DISCUSSION MATERIALS FEBRUARY 2025 CONFIDENTIAL Table of Contents PROJECT SALVARE Preliminary Value Creation Analysis of a Potential Transaction Overview of a Potential Generics Separation 4 Appendix Strategic Perspectives on a Potential Transaction 2 3 1 Executive Summary PROJECT SALVARE 3 Preliminary and Illustrative • Given the clear alignment of the Ma |
|
| March 13, 2025 |
Exhibit 4.5 EXECUTION VERSION SUPPLEMENTAL INDENTURE NO. 2 SUPPLEMENTAL INDENTURE NO. 2 (this “Supplemental Indenture”) dated as of November 29, 2024, among each THERAKOS LLC, a Florida limited liability company (the “Released Guarantor”), MALLINCKRODT INTERNATIONAL FINANCE S.A., a public limited liability company (société anonyme) organized under the laws of the Grand Duchy of Luxembourg, having |
|
| March 13, 2025 |
Exhibit 10.23 Form of Forfeiture Agreement AWARD FORFEITURE AGREEMENT This Award Forfeiture Agreement (this “Agreement”) is entered into on this [●] day of [●] 2024 by and between Mallinckrodt plc (the “Company”) and [●] (“Grantee”). RECITALS WHEREAS, in February 2024, the Company granted to Grantee [●] time-vesting restricted units (the “Award”) subject to the Mallinckrodt Pharmaceuticals 2024 St |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Valued Mallinckrodt Partner, I am reaching out to share some exciting news regarding Mallinckrodt. We just announced that we have agreed to combi |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 27, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number : 001-35803 Mallinckrodt plc (Exact |
|
| March 13, 2025 |
Global Insider Trading Policy. Exhibit 19.1 Effective Date: January 31, 2025 Table of Contents Section 1 – Statement of Policy 3 Section 2 – Purpose of this Policy 3 Section 3 – Policy Owner and Statement of Responsibility 3 Section 4 – Procedures for all Covered Persons 3 Section 5 – Special Procedures for the Window Group 6 Section 6 – Post-Termination Transactions 7 Section 7 – Exceptions 7 Section 8 – Consequences of Violat |
|
| March 13, 2025 |
Exhibit 99.1 Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader Transaction Brings Together Two Highly Complementary Businesses to Broaden Patient Access and Develop New Therapies to Address Unmet Patient Needs Combined Company Expected to Benefit from Immediate Scale, Robust Cash Flow and Enhanced Financial Flexibility to Invest in Internal and Externa |
|
| March 13, 2025 |
Exhibit 21.1 SUBSIDIARIES OF MALLINCKRODT PLC The following is a list of subsidiaries of Mallinckrodt plc as of December 27, 2024. Name of Subsidiary Jurisdiction of Incorporation/Organization Cache Holdings Limited Bermuda Carnforth Limited Bermuda Dritte CORSA Verwaltungsgesellschaft GmbH Germany Ikaria Australia Pty Ltd Australia Ikaria Canada Inc. Canada IMC Exploration Company Maryland Infaca |
|
| March 13, 2025 |
Exhibit 2.1 EXECUTION VERSION TRANSACTION AGREEMENT by and among Mallinckrodt plc, Endo, Inc., and Salvare Merger Sub LLC, dated as of March 13, 2025 TABLE OF CONTENTS 1. INTERPRETATION 2 1.1 Certain Definitions 2 1.2 Terms Defined Elsewhere 22 1.3 Construction 24 1.4 Captions 25 1.5 Time 25 2. SCHEME 25 2.1 Scheme 25 2.2 Change in Shares 25 3. IMPLEMENTATION OF THE SCHEME; COURT MEETINGs AND EGM |
|
| March 13, 2025 |
Exhibit 99.2 Creating a Global, Scaled, Diversified Pharmaceuticals Leader 0 March 13, 2025 Disclosures No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such of |
|
| March 13, 2025 |
Exhibit 10.1 FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 13, 2025 (the “Agreement Date”), by and among (i) Mallinckrodt plc,, a public limited company incorporated in Ireland (hereinafter called “Macaw”), (ii) Endo, Inc., a Delaware corporation (hereinafter called “Eagle”), and (iii) [ ], a shareholder of Mac |
|
| March 13, 2025 |
Exhibit 10.15 AMENDMENT NO. 1 TO THE MALLINCKRODT PHARMACEUTICALS 2024 STOCK AND INCENTIVE PLAN This Amendment No. 1 (“Amendment”) to the Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (the “Plan”) is adopted by the Board of Directors of Mallinckrodt public limited company (the “Company”), to be effective as of December 2, 2024. 1. Purpose. The purpose of this Amendment is to amend the |
|
| March 13, 2025 |
Exhibit 10.16 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTATED RESTRICTED |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) |
|
| March 13, 2025 |
Exhibit 10.1 FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 13, 2025 (the “Agreement Date”), by and among (i) Mallinckrodt plc,, a public limited company incorporated in Ireland (hereinafter called “Macaw”), (ii) Endo, Inc., a Delaware corporation (hereinafter called “Eagle”), and (iii) [ ], a shareholder of Mac |
|
| March 13, 2025 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the share capital of Mallinckrodt plc (“Mallinckrodt” or the “Company”) is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (the “Companies Act”) and the comp |
|
| March 13, 2025 |
Exhibit 99.2 Creating a Global, Scaled, Diversified Pharmaceuticals Leader 1 March 13, 2025 Disclosures No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such of |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Valued Mallinckrodt Partner, I am reaching out to share some exciting news regarding Mallinckrodt. We just announced that we have agreed to combi |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) Dear Valued Mallinckrodt Partner, I am reaching out to share some exciting news regarding Mallinckrodt. We just announced that we have agreed to combi |
|
| March 13, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo, Inc. (Commission File No. 333-280767) [Name] [Address] By email only RE: Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader 13 March 2025 Dear |
|
| March 13, 2025 |
Exhibit 10.17 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTA |
|
| March 13, 2025 |
Filed by Mallinckrodt plc (Commission File No. 001-35803) Filed by Mallinckrodt plc (Commission File No. 001-35803) Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed Pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Endo Inc. (Commission File No. 333-280767) Social Media Posts LinkedIn X (Twitter) |
|
| December 5, 2024 |
Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTATED PERFOR |
|
| December 5, 2024 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTATED PERFORMANCE |
|
| December 5, 2024 |
Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF SECOND AMENDED AND RESTAT |
|
| December 5, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MALLINCKRODT PLC SECOND AMENDED AND RESTATED LONG-TERM TRANSACTION INCENTIVE PLAN (“Transaction Incentive Plan”) AS AMENDED AND RESTATED ON DE |
|
| December 5, 2024 |
Exhibit 2.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 (this “Amendment”), dated as of November 29, 2024, to the |
|
| December 5, 2024 |
EXHIBIT 99.1 Mallinckrodt Completes Divestiture of Therakos® Business Net Proceeds to Reduce the Company’s Net Debt by More Than 60% DUBLIN, December 2, 2024 – Mallinckrodt plc (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today announced that it has completed the previously announced sale of its Therakos business to CVC Capital Partners Fund IX for a purchase price |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| December 5, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION INTRODUCTORY NOTE Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION INTRODUCTORY NOTE The following unaudited pro forma condensed combined financial information (“Pro Forma Financial Information”) is derived from the historical consolidated financial statements of Mallinckrodt plc (“Mallinckrodt” or the “Company”). The unaudited Pro Forma Financial Information is for informational and illust |
|
| November 21, 2024 |
MNK / Mallinckrodt Plc - New / Bracebridge Capital, LLC - SC 13D/A Activist Investment SC 13D/A 1 d874622dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) John N. Spinney, Jr Bracebridge Capital, LLC 888 Boylston Street, Suite 1500 Bosto |
|
| November 14, 2024 |
MNK / Mallinckrodt Plc - New / Flynn James E Passive Investment SC 13G/A 1 e664008sc13ga-mallinckrodt.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 5, 2024 |
Exhibit 99.1 Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance Achieves Third Quarter Net Sales of $505.5 Million, Reflecting 1.7% Year-Over-Year Growth Reaffirms Full Year Net Sales Guidance and Raises Full Year Adjusted EBITDA Guidance After Adjusting Both Metrics for the Therakos Transaction Delivers Third Consecutive Quarter of Acthar® Gel Growth, Unde |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 27, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35803 Mallinckrodt plc |
|
| October 21, 2024 |
Hudson Bay Capital Management LP - MNKTQ 13GA SC 13G/A 1 mnktq13ga.htm MNKTQ 13GA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) ** (CUSIP Number) May 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| September 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| September 10, 2024 |
EXHIBIT 99.1 MALLINCKRODT PLC SPECIALTY GENERICS SEGMENT ADJUSTED EBITDA (unaudited, in millions) Three Months Ended June 28, 2024 Three Months Ended March 29, 2024 Three Months Ended December 29, 2023 Three Months Ended September 29, 2023 Three Months Ended June 30, 2023 Three Months Ended March 31, 2023 Specialty Generics Adjusted EBITDA 1 $ 94.6 $ 67.6 $ 46.1 $ 64.8 $ 46.1 $ 43.1 MALLINCKRODT P |
|
| August 27, 2024 |
MNK / Mallinckrodt Plc - New / MARATHON ASSET MANAGEMENT LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) August 27, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| August 6, 2024 |
Exhibit 99.1 Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance Achieves Second Quarter Net Sales of $514.3 Million, Reflecting 8.3% Year-Over-Year Growth on a Reported Basis and 8.4% on a Constant Currency Basis Reports Net Loss of $43.3 Million, Reflecting a 94.2% Year-Over-Year Improvement; Delivers Adjusted EBITDA of $174.0 Million, Reflecting 20.8% Ye |
|
| August 6, 2024 |
Mallinckrodt plc Amended and Restated Long-Term Transaction Incentive Plan.* Exhibit 10.7 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MALLINCKRODT PLC AMENDED AND RESTATED LONG-TERM TRANSACTION INCENTIVE PLAN (“Transaction Incentive Plan”) A.Purposes. The Board of Directors ( |
|
| August 6, 2024 |
Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Amended and Restated RESTRICTED UN |
|
| August 6, 2024 |
Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Amended and Restated PERF |
|
| August 6, 2024 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF AMENDED AND RESTATED RESTRICTED UNIT AW |
|
| August 6, 2024 |
EXHIBIT 4.3 SUPPLEMENTAL INDENTURE NO. 1 SUPPLEMENTAL INDENTURE NO. 1 (this “Supplemental Indenture”) dated as of May 1, 2024, among each Subsidiary Guarantor listed on Schedule 1 hereto (the “Released Guarantors”), MALLINCKRODT INTERNATIONAL FINANCE S.A., a public limited liability company (société anonyme) organized under the laws of the Grand Duchy of Luxembourg, having its registered office at |
|
| August 6, 2024 |
Exhibit 10.5 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions OF Amended and Restated PERFORMANCE RESTRI |
|
| August 6, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Amended and Restated REST |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number : 001-35803 Mallinckrodt plc (Ex |
|
| August 6, 2024 |
Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) TERMS AND CONDITIONS OF Amended and Restated PERFORMANCE R |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 5, 2024 |
Exhibit 99.1 Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million Divestiture Advances Mallinckrodt’s Strategic Priorities to Optimize Capital Structure and Focus on Core Areas of Expertise Mallinckrodt to Use Net Proceeds to Reduce Net Debt by More Than 50% CVC Brings Resources and Expertise to Further Develop and Commercialize Therakos DUBLIN and LUXEMBOURG – August |
|
| August 5, 2024 |
Exhibit 2.1 EXECUTION VERSION PURCHASE AND SALE AGREEMENT BY AND BETWEEN MALLINCKRODT PLC SOLARIS BIDCO LIMITED SOLARIS IPCO LIMITED AND SOLARIS US BIDCO, LLC Dated as of August 3, 2024 EXECUTION VERSION Table of Contents Page Article I DEFINITIONS 5 Section 1.1 Definitions 5 Section 1.2 Other Defined Terms 31 Article II PURCHASE AND SALE; CLOSING; DEFERRED CLOSINGS 36 Section 2.1 Purchase and Sal |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Commission file number 001-35803 Ireland 98-1088325 (State or other jurisdiction of incorporati |
|
| July 8, 2024 |
MNK / Mallinckrodt Plc - New / Silver Point Capital L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) James Kasmarcik Silver Point Capital, L.P. 2 Greenwich Plaza, Suite 1 Greenwich, CT 06830 203-542-4200 (Name, Addre |
|
| July 8, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.1 2 d851058dex991.htm EX-99.1 Exhibit 1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments th |
|
| June 26, 2024 |
SC 13D/A 1 h13da3.htm SCHEDULE 13D/A, AMENDMENT #3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3)* Under the Securities Exchange Act of 1934 Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) Jay Schoenfarber c/o Hein Park Capital Management LP 888 Seventh Avenue, 41st Floor, Ne |
|
| June 18, 2024 |
MNK / Mallinckrodt Plc - New / GOLDENTREE ASSET MANAGEMENT LP Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G5890A102 (CUSIP N |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 (State or other jurisdiction of incorporation) (Commission File Number) College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland (Address of principal executive offices) (Zip |
|
| May 28, 2024 |
Exhibit 1.01 Conflict Minerals Report Introduction Mallinckrodt plc is a global business consisting of multiple wholly owned subsidiaries (collectively, “Mallinckrodt” or “the Company”) that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. The Company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in speci |
|
| May 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number : 001-35803 Mallinckrodt plc (E |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2024 |
Exhibit 99.1 Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis Reports Net Loss of $65.4 Million, Reflecting a 73.8% Year-Over-Year Improvement; Delivers Adjusted EBITDA of $144.9 Million, Reflecting 17.3% Year-Over-Year G |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* Under the Securities Exchange Act of 1934 Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) Jay Schoenfarber c/o Hein Park Capital Management LP 888 Seventh Avenue, 41st Floor, New York, NY 10019 212-299-4785 (Name, Address and Te |
|
| April 8, 2024 |
Letter from Deloitte & Touche LLP. Exhibit 16.1 April 8, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Mallinckrodt plc’s Form 8-K dated April 8, 2024, and have the following comments: 1. We agree with the statements made in (a) the second sentence of the first paragraph, (b) the second paragraph, (c) the third paragraph, and (d) the fourth paragra |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number : 001-35803 Mallinckrodt plc (Exact |
|
| March 26, 2024 |
Subsidiaries of Mallinckrodt plc. Exhibit 21.1 SUBSIDIARIES OF MALLINCKRODT PLC The following is a list of subsidiaries of Mallinckrodt plc as of December 29, 2023. Name of Subsidiary Jurisdiction of Incorporation/Organization Acthar IP Unlimited Company Ireland Cache Holdings Limited Bermuda Carnforth Limited Bermuda Dritte CORSA Verwaltungsgesellschaft GmbH Germany Ikaria Australia Pty Ltd Australia Ikaria Canada Inc. Canada IMC |
|
| March 26, 2024 |
Form of Second Amended and Restated Employment Agreement for Executive Officers. Exhibit 10.15 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on February 2, 2024 (the “Effective Date”) by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto (the “Company”), and [ ] (the “Executive”) (collectively referred to as “Parties” or individually refer |
|
| March 26, 2024 |
EXHIBIT 10.16 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on February 28, 2024 (the “Effective Date”) by and between Mallinckrodt Pharmaceuticals Ireland Ltd., an Irish limited liability company, or any successor thereto (the “Company”), and Paul O’Neill (the “Executive”) (collectively referred to as “Parti |
|
| March 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 26, 2024 |
Exhibit 99.1 Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance Exceeds High End of Guidance Range on Net Sales and Adjusted EBITDA for Fiscal Year Received U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector (SelfJe |
|
| March 26, 2024 |
cription of Mallinckrodt's Registered Securities. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the share capital of Mallinckrodt plc (“Mallinckrodt” or the “Company”) is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (the “Companies Act”) and the comp |
|
| March 20, 2024 |
MALLINCKRODT PLC Process for Transferring Shares Exhibit 99.1 MALLINCKRODT PLC Process for Transferring Shares 1. Background 1.1 The Company emerged from Chapter 11 on 14 November 2023 (“Emergence”). Upon Emergence, the Company’s existing shares were cancelled and the Company issued new ordinary shares to certain holders of the Company’s debt. 1.2 The new shares are not listed on any stock exchange and are not held through DTC (the settlement an |
|
| March 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2024 |
Squarepoint Ops LLC - AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value US$0.01 per share (Title of Class of Securities) N/A (CUSIP Number) Ronald Veith Squarepoint Ops LLC 250 West 55th Street, 32nd Floor New York, NY 10019 (646) 979-1370 (Name, Address and Teleph |
|
| March 11, 2024 |
SC 13D/A 1 h72224857.htm SCHEDULE 13D/A, AMENDMENT #1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) Jay Schoenfarber c/o Hein Park Capital Management LP 888 Seventh Avenue, 41st Floor, |
|
| February 14, 2024 |
MNK / Mallinckrodt Plc - New / Alta Fundamental Advisers LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 14, 2024 |
MNK / Mallinckrodt Plc - New / Sculptor Capital LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MALLINCKRODT PLC (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
MNK / Mallinckrodt Plc - New / Sculptor Capital LP - SC 13G/A Passive Investment SC 13G/A 1 d767652dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MALLINCKRODT PLC (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) Decem |
|
| February 12, 2024 |
MNK / Mallinckrodt Plc - New / Flynn James E Passive Investment SC 13G/A 1 e619246sc13ga-mallinckrodt.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A |
|
| February 6, 2024 |
MNK / Mallinckrodt Plc - New / Hudson Bay Capital Management LP - MNKTQ 13GA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G5890A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 6, 2024 |
MNK / Mallinckrodt Plc - New / MARATHON ASSET MANAGEMENT LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) November 14, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| February 6, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EX-99.1 2 d760480dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) The undersigned acknowledge and agree that the foregoing Statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this Statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filin |
|
| February 2, 2024 |
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on [ · ] (the “Effective Date”) by and between [ST Shared Services LLC],1 a Delaware limited liability company, or any successor thereto (the “Company”), and [ · ] (the “Executive”) (collectively referred to as “Parties” or individually referred to as a “Party”). |
|
| February 2, 2024 |
Exhibit 10.8 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Performance Restricted Unit Award Decem |
|
| February 2, 2024 |
Exhibit 10.3 MALLINCKRODT PHARMACEUTICALS 2024 STOCK AND INCENTIVE PLAN Effective February 2, 2024 Article I PURPOSE 1.1 Purpose. The purposes of this Plan are to promote the interests of the Company by (i) aiding in the recruitment and retention of Directors, Employees and Consultants, (ii) providing incentives to Directors, Employees and Consultants by means of performance-related incentives to |
|
| February 2, 2024 |
Exhibit 10.7 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Performance Restricted Un |
|
| February 2, 2024 |
Exhibit 10.6 [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on [ · ], 2024 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [ · ] Restricted Units subject to the provisions of these Terms and Conditions a |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| February 2, 2024 |
Exhibit 10.5 [CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on [ · ], 2024 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [ · ] Restricted Units subject to the provisions of these Terms and Conditions and th |
|
| February 2, 2024 |
Exhibit 10.4 [EC other than CEO Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Restricted Unit Award RESTRICTED UNIT AWARD (“Award”) granted on [ · ], 2024 (the “Grant Date”). 1. Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [ · ] Restricted Units subject to the provisions of these Terms and Conditions and the Plan. T |
|
| February 2, 2024 |
Mallinckrodt plc Transaction Incentive Plan.* Exhibit 10.10 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MALLINCKRODT PLC TRANSACTION INCENTIVE PLAN A. Purposes. The Board of Directors (the “Board”) of Mallinckrodt plc (the “Company”), |
|
| February 2, 2024 |
Exhibit 10.9 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Director Form] Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan (“Plan”) Terms and Conditions of Performance Restricted Unit Award |
|
| February 2, 2024 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), is entered into on February 2, 2024 (the “Effective Date”) by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto (the “Company”), and Sigurdur Olafsson (the “Executive”). WHEREAS, the Executive was previously party t |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| January 26, 2024 |
Exhibit 10.1 EXECUTION COPY ST SHARED SERVICES LLC January 25, 2024 Sigurdur Olafsson Dear Siggi, Reference is made to that certain Amended and Restated Employment Agreement by and between you and ST Shared Services LLC, dated as of February 22, 2023, as amended on June 22, 2023 and August 4, 2023 (the “Employment Agreement”) and that certain notice (the “Notice of Termination”) that you delivered |
|
| January 22, 2024 |
MNK / Mallinckrodt Plc - New / Silver Point Capital L.P. - SC 13D/A Activist Investment SC 13D/A 1 d106987dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) James Kasmarcik Silver Point Capital, L.P. 2 Greenwich Plaza, Suite 1 Greenwich, CT 0 |
|
| January 22, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.1 2 d106987dex991.htm EX-99.1 Exhibit 1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments th |
|
| January 17, 2024 |
MNK / Mallinckrodt Plc - New / Hein Park Capital Management LP - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) Jay Schoenfarber c/o Hein Park Capital Management LP 888 Seventh Avenue, 41st Floor, New York, NY 10019 212-299-4785 (Name, Address and Tel |
|
| January 17, 2024 |
EX-3 3 h70223967c.htm SIDE LETTER AGREEMENT Exhibit 3 Privileged & Confidential December 3, 2023 Ladies and Gentlemen: Reference is made herein to the Articles of Association, effective as of the 14th day of November 2023 (the “Constitution”, as may be amended from time to time) of Mallinckrodt plc (the “Company”). Capitalized terms used herein but not otherwise defined have the meanings ascribed |
|
| January 17, 2024 |
EX-1 2 h70223967b.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT THIS JOINT FILING AGREEMENT is entered into as of January 16, 2024 by and among the parties hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the Common Stock, par value $0.01 per share, of Mallinckrodt plc, and any amendment thereafter signed by each of the undersigned shall be (unl |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 4, 2024 |
MNK / Mallinckrodt Plc - New / JPMORGAN CHASE & CO - FILING MALLINCKRODT PLC Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Mallinckrodt plc (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| December 13, 2023 |
MNK / Mallinckrodt Plc - New / GOLDENTREE ASSET MANAGEMENT LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Mallinckrodt plc (Name of Issuer) Ordinary Shares (Title of Class of Securiti |
|
| December 13, 2023 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| November 24, 2023 |
MNK / Mallinckrodt Plc - New / Silver Point Capital L.P. - SC 13D Activist Investment SC 13D 1 d721765dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Mallinckrodt plc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) James Kasmarcik Silver Point Capital, L.P. 2 Greenwich Plaza, Suite 1 Greenwich, CT 06830 2 |
|
| November 24, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.1 2 d721765dex991.htm EXHIBIT 1 Exhibit 1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments |
|
| November 24, 2023 |
EX-99.1 2 eh230423564ex9901.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on |
|
| November 24, 2023 |
MNK / Mallinckrodt Plc - New / Squarepoint Ops LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value US$0.01 per share (Title of Class of Securities) N/A (CUSIP Number) Ronald Veith Squarepoint Ops LLC 250 West 55th Street, 32nd Floor New York, NY 10019 (646) 979-1370 (Name, Address and Telepho |
|
| November 20, 2023 |
MNK / Mallinckrodt Plc - New / Flynn James E Passive Investment SC 13G 1 e619072sc13g-mallinckrodt.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* Mallinckrodt plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G5890A102 |
|
| November 17, 2023 |
MNK / Mallinckrodt Plc - New / Bracebridge Capital, LLC - SC 13D/A Activist Investment SC 13D/A 1 d846461dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mallinckrodt plc (Name of Issuer) Shares of Common Stock, par value $0.01 per share (Title of Class of Securities) G5890A102 (CUSIP Number) John N. Spinney, Jr Bracebridge Capital, LLC 888 Boylston Street, Suite 150 |
|
| November 15, 2023 |
Exhibit 10.1 CONTINGENT VALUE RIGHT AGREEMENT BETWEEN MALLINCKRODT PLC, AND OPIOID MASTER DISBURSEMENT TRUST II November 14, 2023 Table of Contents Page SECTION 1. Issuance of CVRs 1 SECTION 2. Nontransferable 1 SECTION 3. Duration and Exercise of CVRs 2 SECTION 4. Cancellation of CVRs 4 SECTION 5. Adjustments of Exercise Price and CVR Number 4 SECTION 6. Fractional CVR Shares 14 SECTION 7. Redemp |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| November 15, 2023 |
Exhibit 10.5 FIRST LIEN INTERCREDITOR AGREEMENT among MALLINCKRODT PLC, as the Parent, MALLINCKRODT INTERNATIONAL FINANCE S.A., as the Lux Borrower, MALLINCKRODT CB LLC, as the Co-Borrower, the other Grantors from time to time party hereto, ACQUIOM AGENCY SERVICES LLC, as Collateral Agent for the Pari Passu Secured Parties and as the Authorized Representative for the Credit Agreement Secured Parti |
|
| November 15, 2023 |
Exhibit 99.1 Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 Moving Forward as a Stronger Company With a Significantly Improved Balance Sheet and Increased Financial Flexibility David Stetson and Jon Zinman Appointed to New Board of Directors DUBLIN – November 14, 2023 – Mallinckrodt plc (“Mallinckrodt” or the “Company”), a global speci |
|
| November 15, 2023 |
Exhibit 10.3 Dated November 14, 2023 MALLINCKRODT PLC Deed Poll relating to the Information Rights Members of Mallinckrodt plc THIS DEED POLL is made on November 14, 2023 by MALLINCKRODT PUBLIC LIMITED COMPANY (the “Company”), a company incorporated under the laws of Ireland with registration number 522227 and having its principal place of business at College Business and Technology Park, Cruisera |
|
| November 15, 2023 |
As filed with the Securities and Exchange Commission on November 15, 2023 As filed with the Securities and Exchange Commission on November 15, 2023 No. 333-266012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-266012 UNDER THE SECURITIES ACT OF 1933 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 98-1088325 (State or other Jurisdiction of In |
|
| November 15, 2023 |
Exhibit 3.1 Companies Act 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM and ARTICLES OF ASSOCIATION of MALLINCKRODT PUBLIC LIMITED COMPANY (Adopted on 14 November 2023) Cert. No.: 522227 Companies Act 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION of MALLINCKRODT PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION 1. The name of the Company is Mallinckrodt public limited company. 2. The Co |
|
| November 15, 2023 |
Exhibit 10.4 CREDIT AGREEMENT Dated as of November 14, 2023 among MALLINCKRODT PLC, as the Parent, MALLINCKRODT INTERNATIONAL FINANCE S.A., as Lux Borrower, MALLINCKRODT CB LLC, as Co-Borrower, THE LENDERS PARTY HERETO FROM TIME TO TIME, ACQUIOM AGENCY SERVICES LLC and SEAPORT LOAN PRODUCTS LLC, as Co-Administrative Agents, and ACQUIOM AGENCY SERVICES LLC, as Collateral Agent TABLE OF CONTENTS Pag |
|
| November 15, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (including all exhibits hereto and as may be amended, supplemented or restated from time to time in accordance with the terms hereof, this “Agreement”) is made and entered into as of November 14, 2023, by and among Mallinckrodt plc, an Irish public limited company (the “Company”), and the Initial Holders (as defined belo |
|
| November 15, 2023 |
Exhibit 4.1 MALLINCKRODT INTERNATIONAL FINANCE S.A. MALLINCKRODT CB LLC as Issuers the Guarantors party hereto from time to time 14.750% First Lien Senior Secured Notes due 2028 INDENTURE Dated as of November 14, 2023 Wilmington Savings Fund Society, FSB, as First Lien Trustee and Acquiom Agency Services LLC, as First Lien Collateral Agent TABLE OF CONTENTS Page Article I DEFINITIONS AND INCORPORA |
|
| November 13, 2023 |
Exhibit 99.2 High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement Company Expects to Complete Irish Examinership and Emerge from Chapter 11 in Coming Days DUBLIN – November 10, 2023 – Mallinckrodt plc (OTCMKTS: MNKTQ) (in examination under Part 10 of the Companies Act 2014 of Ireland, and hereinafter “Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today an |
|
| November 13, 2023 |
Exhibit 99.1 H.COS.20230000173 FRIDAY THE 10TH DAY OF NOVEMBER 2023 BEFORE MR JUSTICE MICHAEL QUINN IN THE MATTER OF MALLINCKRODT PUBLIC LIMITED COMPANY AND IN THE MATTER OF PART 10 OF THE COMPANIES ACT 2014 The application of Michael McAteer (the Examiner to Mallinckrodt Public Limited Company (the Company)) for the confirmation of the Examiner’s proposals for a scheme of arrangement in |
|
| November 13, 2023 |
Exhibit 2.1 SCHEDULE 1 THE PROPOSALS THE HIGH COURT H.COS.2023.0000173 IN THE MATTER OF MALLINCKRODT PUBLIC LIMITED COMPANY AND IN THE MATTER OF THE COMPANIES ACTS 2014 TO 2020 PROPOSALS FOR A COMPROMISE AND SCHEME OF ARRANGEMENT BETWEEN MALLINCKRODT PUBLIC LIMITED COMPANY AND ITS MEMBERS AND CREDITORS DATED 9 OCTOBER 2023 Michael McAteer Examiner |
|
| November 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 Mallinckrodt plc (in examination under Part 10 of the Companies Act 2014 of Ireland) (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088 |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number : 001-35803 Mallinckrodt pl |
|
| November 7, 2023 |
EXHIBIT 10.16 AMENDMENT TO OPIOID MDT II COOPERATION AGREEMENT This AMENDMENT TO THE OPIOID MDT II COOPERATION AGREEMENT, dated as of August 23, 2023 (this “Amendment”), is entered into by and among MALLINCKRODT PLC and its undersigned affiliates (each individually a “Mallinckrodt Entity” and collectively “Mallinckrodt”), and the Opioid Master Disbursement Trust II (the “Trust”). Capitalized terms |
|
| November 7, 2023 |
EXHIBIT 10.15 FINAL AMENDMENT TO OPIOID DEFERRED CASH PAYMENTS AGREEMENT This final AMENDMENT TO THE OPIOID DEFERRED CASH PAYMENTS AGREEMENT, dated as of August 23, 2023 (this “Final Amendment”), is entered into by and among MALLINCKRODT PLC, a public limited company incorporated in Ireland with registered number 522227 (the “Parent”), MALLINCKRODT LLC, a Delaware limited liability company (“MLLC” |
|
| November 7, 2023 |
Exhibit 99.1 Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results Third Quarter Net Sales of $497.0 Million Reflects 6.8% Growth Compared to the Prior Year Quarter Acthar® Gel (Repository Corticotropin Injection) Delivery Device Supplemental New Drug Application Accepted by U.S. Food and Drug Administration Financial Restructuring Plan Approved by U.S. Bankruptcy Court; |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Mallinckrodt plc (in examination under Part 10 of the Companies Act 2014 of Ireland) (Exact name of registrant as specified in its charter) Ireland 001-35803 98-10883 |
|
| October 10, 2023 |
Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan Exhibit 99.2 Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan DUBLIN, October 10, 2023 – Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today announced that its Plan of Reorganization (the “Plan”) has been confirmed by the U.S. Bankruptcy Court for the District of Dela |
|
| October 10, 2023 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: MALLINCKRODT PLC, et al., Debtors.1 ) ) ) ) ) ) ) ) Chapter 11 Case No. 23-11258 (JTD) (Jointly Administered) ORDER APPROVING (I) THE DISCLOSURE STATEMENT AND (II) CONFIRMING THE FIRST AMENDED PREPACKAGED JOINT PLAN OF REORGANIZATION OF MALLINCKRODT PLC AND ITS DEBTOR AFFILIATES UNDER CHAPTER 11 OF THE BANKRUPTC |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Mallinckrodt plc (in examination under Part 10 of the Companies Act 2014 of Ireland) (Exact name of registrant as specified in its charter) Ireland 001-35803 98-10883 |
|
| October 10, 2023 |
Exhibit 2.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: MALLINCKRODT PLC, et al., Debtors.1 ) ) ) ) ) ) ) ) Chapter 11 Case No. 23-11258 (JTD) (Jointly Administered) FIRST AMENDED PREPACKAGED JOINT PLAN OF REORGANIZATION OF MALLINCKRODT PLC AND ITS DEBTOR AFFILIATES UNDER CHAPTER 11 OF THE BANKRUPTCY CODE Mark D. Collins (No. 2981) George A. Davis (admitted pro hac vi |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| September 21, 2023 |
Exhibit 99.1 Independent Experts Report S.511 of the Companies Act 2014 Mallinckrodt Public Limited Company 16 September 2023 (as updated on 20 September 2023) James Anderson Deloitte Ireland LLP 29 Earlsfort Terrace Dublin 2 Table of Contents 1. Introduction 3 2. Section 511 (3) (a) Companies Act 2014 – Officers of the Company 18 3. Section 511 (3) (b) Companies Act 2014 – Other Directorships 20 |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| September 11, 2023 |
Exhibit 10.1 Execution Version SUPERPRIORITY SENIOR SECURED DEBTOR-IN-POSSESSION CREDIT AGREEMENT Dated as of September 8, 2023 among MALLINCKRODT PLC, as the Parent, a Debtor and a Debtor-in-Possession, MALLINCKRODT INTERNATIONAL FINANCE S.A., as Lux Borrower, a Debtor and a Debtor-in-Possession, MALLINCKRODT CB LLC, as Co-Borrower, a Debtor and a Debtor-in-Possession, THE LENDERS PARTY HERETO, A |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Mallinckrodt plc (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation) (Commission File |
|
| September 6, 2023 |
Originator Performance Guaranty, dated as of August 30, 2023. Exhibit 10.2 Execution Version ORIGINATOR PERFORMANCE GUARANTY This ORIGINATOR PERFORMANCE GUARANTY (as amended, supplemented or otherwise modified from time to time, this “Performance Guaranty”), dated as of August 30, 2023, is made by each of the Originators (as defined below) in favor of BARCLAYS BANK PLC, as administrative agent (together with its successors and assigns in such capacity, the “ |
|
| September 6, 2023 |
Performance Guaranty, dated as of August 30, 2023. Exhibit 10.3 Execution Version PERFORMANCE GUARANTY This PERFORMANCE GUARANTY (as amended, supplemented or otherwise modified from time to time, this “Performance Guaranty”), dated as of August 30, 2023, is made by MEH, INC., a Nevada corporation (the “Performance Guarantor” and, in its individual capacity, “MEH”), in favor of BARCLAYS BANK PLC, as administrative agent (together with its successor |
|
| September 6, 2023 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the Ordinary Shares of Mallinckrodt plc (the "Company") from listing and registration on the Exchange at the opening of business on September 18, 2023, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Ordinary Shares are no longer suitable for continued listing and trading on the Exchange. |
